<DOC>
	<DOCNO>NCT00204594</DOCNO>
	<brief_summary>Phase I/II clinical trial analyze safety efficiency intralesional application bispecific single chain antibody rM28 autologous PBMCs patient metastatic melanoma stage III/IV unresectable metastasis .</brief_summary>
	<brief_title>Local Treatment Metastatic Melanoma With Autologous Lymphocytes Bispecific Antibody rM28</brief_title>
	<detailed_description>Phase I/II clinical trial analyze safety efficiency intralesional application bispecific single chain antibody rM28 autologous PBMCs patient metastatic melanoma stage III/IV unresectable metastasis . The antibody direct epitops human CD28 melanoma associate surface antigen HMV-MAA . Treatment 5 day dose escalation .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>malignant melanoma stage III/IV injectable soft tissue metastasis inform consent give Karnofsky &gt; = 70 % additional chemotherapeutical treatment systemic glucocorticoid brain metestasis malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>mRNA</keyword>
	<keyword>vaccination</keyword>
	<keyword>melanoma</keyword>
</DOC>